Neuron23

Changing the future of Parkinson's disease.

South San Francisco, United States · Founded 2018 · $312.5M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$312.5M
Last Round
$2.5M GrantJun 2026
Rounds
5

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 5 investors for this company. The full record is or through the API.

About

Neuron23 is a clinical-stage biotechnology company combining human genetics and data science to develop precision medicines for Parkinson's disease. Its lead program targets LRRK2, a genetic driver of Parkinson's, using machine learning and functional genomics to identify and match patients to therapies. The company was founded in 2018 by a team of drug hunters, geneticists, and neuroscientists.

Summary

Neuron23 is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $312.5M in total across 5 rounds, most recently a $2.5M Grant round in Jun 2026. Investors include Westlake Village BioPartners, Blue Owl Capital and SoftBank.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantMichael J. Fox Foundation GrantJun 2026
$2.5M

Sign up to see all 5 events

Funding: Series A through Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$2.1BJun 2026
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Artificial Intelligence, Healthcare
Series ETotal funding$1.1BJun 2022
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Neuron23 on Indexed.vc
<a href="https://indexed.vc/companies/neuron23"><img src="https://indexed.vc/api/badge/company/neuron23" alt="Neuron23 on Indexed.vc" width="260" height="76" /></a>